![Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | Journal of Medicinal Chemistry Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.5b01073/asset/images/large/jm-2015-010738_0003.jpeg)
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | Journal of Medicinal Chemistry
![Pharmaceutics | Free Full-Text | Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors Pharmaceutics | Free Full-Text | Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-12-01205/article_deploy/html/images/pharmaceutics-12-01205-g001.png?1607688774)
Pharmaceutics | Free Full-Text | Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors
![Pharmaceutics | Free Full-Text | Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors Pharmaceutics | Free Full-Text | Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-12-01205/article_deploy/html/images/pharmaceutics-12-01205-ag.png?1607688777)